Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Tremelimumab Monotherapy in Advanced Solid Tumors
2015-002934-32Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in Nonhematologic neoplasms, bladder cancer, pancreatic adenocarcinoma (PDAC) and 1 more, sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Sep 2015; status: completed.
02
Drugs
tremelimumab
03
Conditions
Nonhematologic neoplasmsbladder cancerpancreatic adenocarcinoma (PDAC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2015-002934-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002934-32.